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Abstract 26 
 27 
Traumatic spinal cord injury results in severe and irreversible loss of function. The injury 28 
triggers a complex cascade of inflammatory and pathological processes, culminating in the 29 
formation of a scar. While traditionally referred to as a glial scar, the spinal injury scar in fact 30 
comprises multiple cellular and extracellular components. This multidimensional nature should 31 
be considered when aiming to understand the role of scarring in limiting tissue repair and 32 
recovery. In this Review we discuss recent advances in understanding the composition and 33 
phenotypic characteristics of the spinal injury scar, the oversimplification of defining the scar 34 
in binary terms as good or bad, and the development of therapeutic approaches to target scar 35 
components to enable improved functional outcome after spinal cord injury.  36 
 37 
 38 
Introduction 39 
 40 
It is estimated that more than 27 million people worldwide are living with long-term disability 41 
following a spinal cord injury1, 90% of which result from trauma and 10% as a secondary 42 
consequence of disease. Following traumatic spinal cord injury, death of spinal neurons at the 43 
injury level leads to paralysis of denervated musculature and the disruption of long spinal 44 
tracts leads to loss of sensation and motor control — injured descending axonal projections 45 
can no longer innervate motor neuron pools below the injury level, and injured ascending 46 
axonal projections can no longer provide appropriate transmission of sensory information to 47 
the brain. This results in the dysregulation of multiple organ systems throughout the body and 48 
a devastating loss of function2. Despite recent progress in developing experimental 49 
therapeutics aimed at enhancing tissue repair and neuroplasticity, there are still no effective 50 
pathology-modifying or regenerative treatments available to spinal injured individuals3,4. 51 
Following diagnosis and acute medical interventions to stabilize clinical status, the outcome 52 
is largely determined by the management of resultant symptoms, and rehabilitation to 53 
maximize residual neural function2. 54 
 55 
The lack of repair following spinal cord injury is due to both cell intrinsic factors and the 56 
extrinsic injury environment. Neurons of the adult mammalian central nervous system (CNS) 57 
have low intrinsic regenerative ability due to a lack of growth driving signals, and suboptimal 58 
availability or arrangement of subcellular machinery to enable growth cone reformation and 59 
axonal elongation5.  Experimental efforts to unlock regeneration potential at the level of the 60 
cell body of the neuron have focussed on growth signalling pathways, individual regeneration-61 
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associated genes, and transcriptional and epigenetic networks6-9. Regenerative strategies 62 
have also aimed to increase synthesis and transport of materials required for growth and 63 
modulate axonal cytoskeletal dynamics to promote elongation or branching6,7,10-12.  64 
 65 
The injury microenvironment also plays a key role in limiting functional repair after spinal cord 66 
injury, an important component of which is the formation of a scar. As a healing response, the 67 
scar acts to spatially contain and isolate damage. However, reactive injury processes fail to 68 
restore spinal tissue architecture and composition, pathology continues to propagate and the 69 
tissue within and around the scar remains dysfunctional. Moreover, within the scar there are 70 
extracellular factors which themselves actively inhibit restoration of function. These act acutely 71 
and chronically to prohibit compensatory changes in neurons which, perhaps if overcome, 72 
could transform the scar into a more effective repair process which both isolates damage and 73 
generates an environment in which injury could be surmountable.  74 
 75 
Here we review  recent literature regarding the composition and role of the spinal injury scar, 76 
including processes leading to scar formation and maintenance, the cellular and extracellular 77 
components of the scar, and how these interact with other mediators of tissue pathology. We 78 
discuss the complexities of the scar and its seemingly opposing roles, often classified in an 79 
overly simplistic manner as good or bad, and finally we discuss the potential for therapeutic 80 
targeting of the scar to achieve functional repair of the injured spinal cord. 81 
 82 
 83 
Scar formation and maintenance 84 
Tissue scarring in periphery and CNS 85 
Injury to any tissue results in a healing response, the purpose of which is firstly to curtail 86 
damage and restore homeostasis and then, where possible, to restore tissue and organ 87 
function. Inflammation, tissue reformation (involving cell proliferation and/or migration) and 88 
tissue remodelling are conserved repair processes, although their success in restoring 89 
function varies across different tissues. A scar consists of the cells and extracellular matrix 90 
(ECM) formed as the result of attempted wound repair. In many organs, the formation of a 91 
scar is associated with a resolution phase and restoration of key functions of the tissue. The 92 
healed tissue may not directly recapitulate the pre-injury state but it regains some ability to 93 
execute its original function13. However, the process of tissue scarring in the CNS is more 94 
complex than for many other tissues, and is associated with chronic non-resolving pathology. 95 
 96 
Disease and injury to the CNS is almost always accompanied by some degree of reactive 97 
gliosis, inflammation and scarring. Scar tissue and associated deposition of ECM molecules 98 
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such as chondroitin sulfate proteoglycans (CSPGs, discussed in more detail below) has been 99 
reported in humans and experimental animal models following traumatic brain injury14 and 100 
stroke15, as well in neurodegenerative disorders such as Alzheimer’s Disease16, and disorders 101 
with a predominantly demyelinating and inflammatory pathology such as multiple sclerosis17,18. 102 
However, despite the occurrence of reactive tissue changes and scarring in several other CNS 103 
pathologies, spinal cord injury represents a particularly striking example where wound repair 104 
is inefficient and injury-induced pathological changes are insurmountable.  105 
 106 
There are several likely contributing factors to these regional and injury-specific differences in 107 
CNS scarring. Cell types involved in scarring in different CNS regions are phenotypically 108 
different19. There are also differences in the levels of neuroinflammation and astrocyte 109 
activation after brain and spinal cord trauma, with increased expression of inflammatory 110 
cytokines and potentially damaging leukocytes20-22 and  more abundant and widespread 111 
astrocytosis in spinal cord injuries compared to brain injuries14,20. There are also differences 112 
in ECM composition and distribution between brain and spinal cord pathologies23-25. In this 113 
review we specifically focus on scarring following spinal cord injury, and discuss the dynamic 114 
cellular and extracellular interactions that culminate in a hostile scar environment with limited 115 
capacity for repair. 116 
 117 
Defining the spinal injury scar 118 
The scar that forms after a spinal cord injury is generally considered to have two distinct 119 
components: the lesion core, which is primarily composed of stromal-derived fibroblasts and 120 
inflammatory immune cells, and the lesion border, or penumbra, which surrounds the core 121 
and is primarily composed of hypertrophic astrocytes26-28. The term glial scar has historically 122 
been used to describe the astrocyte border component of the scar29-31, although some 123 
investigators use the term more widely to reflect the entire lesion including both glial and non-124 
neural components32. Other distinctions have been made between the glial scar and the 125 
fibrotic scar33, and specific components of the lesion (the core, the astrocyte border, and 126 
surrounding tissue) have recently been referred to as lesion-related tissue compartments31. 127 
While these distinctions are valid, and scar components undoubtedly become spatially 128 
compartmentalized in a chronic scar, these components are nonetheless interlinked, and 129 
evidence suggests that there may be temporal dependence and bi-directional cross talk 130 
between them. Furthermore, the scar should not be considered as an isolated component of 131 
spinal injury pathology since it is spatio-temporally shaped by processes of inflammation and 132 
tissue and matrix remodeling. Here we use the term spinal injury scar, which encompasses 133 
both cellular and extracellular components across the lesion core, lesion border and 134 
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surrounding penumbra (Figure 1). Below, we discuss the events after the initial spinal cord 135 
trauma that contribute to spinal injury scar formation and maintenance 136 
 137 
Acute signaling events post-injury 138 
 139 
The majority of spinal cord injuries feature a contusive component, where compromised spinal 140 
canal shape or volume causes physical deformation of spinal cord tissue2 (rarer presentations 141 
include sharp penetrating trauma to the spinal cord, or purely ischemic lesions following 142 
vascular compromise). Tissue deformation transmits shearing and compressive forces on 143 
axons and blood vessels and initiates a cascade of pathological processes. Below, we discuss 144 
these processes, focusing on changes occurring immediately after the initial spinal cord 145 
trauma up to one day post injury. These acute post-injury events signal the beginning of the 146 
injury cascade, which culminates in chronic pathology and scarring (summarized in Figure 2). 147 
 148 
Vascular trauma leads to hemorrhage, and accumulating blood sera increases tissue colloid 149 
osmotic pressure, causing local edema and swelling34. This damage, along with vasospasm 150 
of spared vessels, leads to tissue ischemia.  ATP released from damaged or metabolically-151 
compromised cells acts on purinergic receptors to induce microglial chemotaxis towards the 152 
injury zone to protect against spread of damage35-38. ATP gradients are also propagated via 153 
connexins39. Oligodendrocytes, oligodendrocyte precursor cells (OPCs), microglia and 154 
astrocytes express a heterogeneous mix of P2 receptor subtypes, and respond reactively to 155 
increasing levels of ATP following trauma40,41.  156 
Subsequently, tissue reperfusion induces further oxidative stress, glutamate release and 157 
death of neighbouring neurons and glia via excitotoxicity42. ATP release, dramatic loss of 158 
cellular and extracellular ionic homeostasis and excessive calcium levels results in the 159 
activation of calpains, phospholipase A2 and lipoxogenase. This is followed by the generation 160 
of bioactive lipid mediators and free radicals43. Progressive oxidation of fatty acids in cell 161 
membranes and myelin (lipid peroxidation) occurs. Furthermore there is feed-forward 162 
propagation of the injury and cell reactivity, as bioactive mediators potentiate ATP-mediated 163 
calcium increases in glia40 and additional blood vessel endothelial cell damage results in an 164 
expanding zone of hemorrhagic necrosis44.  165 
 166 
Concomitantly, hemostasis is the first stage of wound healing: endothelial cell trauma results 167 
in platelet adhesion and activation, the coagulation cascade, and thrombin-mediated 168 
conversion of fibrinogen to fibrin, to form a clot. The onset of hemostasis45 is associated with 169 
reactive changes in resident glia and represents a potent inflammatory stimulus. Platelets 170 
themselves are an abundant source of inflammatory peptides and protein mediators and 171 
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release cytokines, chemokines and eicosanoids which readily communicate with resident 172 
spinal cord cells and non-resident leukocytes. These signals cause rapid neutrophil infiltration 173 
within an hour (peaking within 24 hours), which secrete MMP9, a type IV collagenase which 174 
acts on basement membranes to further permeabilise the blood brain barrier34. Furthermore, 175 
cellular and extracellular factors (which are rapidly induced as a result of trauma, injury 176 
expansion and necrosis) constitute host-derived danger signals46. Damage associate 177 
molecular patterns (DAMPs) are sterile inflammatory stimuli (such as ATP, HMGB1, IL33) 178 
which activate prototypical pathogen recognition receptors (TLRs, NLRs, signalling via MAPK, 179 
NFB) to induce secretion of proinflammatory cytokines and chemokines from both neurons 180 
and glia, compounding reactive gliosis and acting to recruit circulating immune responders47-181 
50.  182 
 183 
Non-resolving pathology 184 
Non-resolving pathology results in incomplete tissue repair and formation of a scar. Each cell 185 
type that contributes to non-resolving pathology, and its respective phenotype, is inherently 186 
linked to the environment it finds itself in. This environment constitutes a milieu of other 187 
resident and non-resident cells, the signals they transmit and the biochemical and biophysical 188 
properties of the extracellular environment in which they reside. Below, we first discuss cellular 189 
and extracellular changes occurring in the sub-acute period, from days to several weeks after 190 
the initial spinal cord trauma, and their contribution to the spinal injury scar. Cellular and 191 
extracellular components of the spinal injury scar in the acute and chronic phases of spinal 192 
cord injury are depicted in Figure 1. 193 
 194 
Cellular components of the scar 195 
Astrocytes 196 
Astrocytes become reactive following spinal cord injury. The degree of reactivity is influenced 197 
by a number of cell-surface receptors for DAMPS and proinflammatory cytokines and 198 
chemokines51, and ranges from temporary changes in gene expression and cell morphology 199 
to significant hypertrophy, spatial rearrangement and proliferation (collectively termed 200 
astrogliosis)52,53. Additionally, diverse astrocyte subsets and phenotypes may exist following 201 
spinal cord injury (Box 1). Astrocytes are also known to dynamically switch from reactive to 202 
quiescent when transposed from injured to naïve spinal cord54. Reactive astrocytes densely 203 
populate the borders of the injury epicentre, hypertrophy and strongly upregulate the 204 
expression of intermediate filament proteins such as GFAP, nestin and vimentin53,55,56. This 205 
corresponds with elongation and extension of overlapping processes (unlike parallel and radial 206 
processes found throughout normal CNS tissue architecture) and the organization of 207 
astrocytes into a barrier-like structure57.  208 
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 209 
This barrier is reinforced by proliferation and organization of a local astrocyte population at the 210 
injury border, thought to be mediated via STAT-3 dependent signalling58,59 and leucine zipper-211 
bearing kinase (LZK, MAP3K13) expression56. Ependymal cell-derived astrocyte-like progeny 212 
contribute to this population of astrocytes in certain spinal injury models60, though evidence 213 
suggests this is of minor contribution following contusive injuries61. Tight linking of astrocytes 214 
at the injury borders is associated with reformation of the glia limitans and the containment of 215 
immune cells and fibroblast-like cells within the injury epicenter, via ephrin-mediated cellular 216 
adhesion62,63. Thus, a population of reactive astrocytes act to spatially isolate damage and 217 
fibrosis from spared tissue.  218 
 219 
An overlapping population of astrocytes are further associated with the chronic maintenance 220 
of this structure. These are referred to as scar forming astrocytes64.. Though astrocytes alone 221 
are not responsible for the formation of a scar, they are major cellular players activated and 222 
maintained during post-injury pathology, inflammation and tissue and matrix remodelling. 223 
Alongside other cells and extracellular factors, astrocytes shape the scar cellular and 224 
extracellular milieu sub-acutely and chronically. 225 
 226 
Fibroblast-like cells 227 
Fibroblasts are ubiquitous in peripheral connective tissues and organs and are the principal 228 
generators of stroma, including the ECM. By contrast, under normal conditions within the CNS, 229 
fibroblast-like cells are mostly associated with the vasculature, and contribute only to the basal 230 
laminae. However, injury to the spinal cord induces a significant fibroblast response which 231 
produces matrix components. These matrix components may inhibit neural regeneration 232 
directly, and promote prolonged tissue remodelling via interaction with inflammatory cells 233 
(detailed below). These stromal elements become spatially compartmentalised by 234 
surrounding reactive astrocytes to form the fibrotic core of the spinal injury scar.  235 
 236 
Fibroblasts proliferate from meningeal cells if the dura is compromised27,33 and can derive from 237 
perivascular cells in rats65 and mice63 following contusion injury. There is some evidence that 238 
fibroblast-like stromal cells derive from pericytes; the PDGFRβ+ Glast+ perivascular cell 239 
population, termed type A pericytes, proliferate in response to injury and contribute to fibrotic 240 
scarring66. Preventing Glast1+ cell proliferation leads to failure of wound sealing, exacerbated 241 
lesion volume and decreased matrix deposition66, whereas moderate reduction of pericyte-242 
derived fibrosis was found to reduce scar pathology and confer functional recovery67. 243 
However, whether this is a truly separate population or whether it overlaps with known cell 244 
types (such as Glast+ astrocytes in the glia limitans) is unclear.  245 
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 246 
An increase in type-1 pericytes (distinct from those described above) has also been described, 247 
following a non-contusive dorsal funiculus lesion using  a nestin-GFP/NG2-DsRed transgenic 248 
mouse line 68. However, NG2 is also a marker of OPCs, Schwann cells and macrophages 249 
following spinal cord injury69. Thus, there is some ambiguity as to the response of pericytes 250 
following injury, although collectively there is evidence that fibroblast-like cells are derived 251 
from a perivascular PDGFRβ+ origin63,66,70. 252 
   253 
Oligodendrocyte precursor cells 254 
NG2+ OPCs become reactive after spinal cord injury, have a significant proliferative capacity 255 
and are spatially intermingled with other reactive glia at the injury border71,72. Two main 256 
contributions of OPCs within the spinal injury scar environment have been described, with 257 
seemingly opposing roles. OPCs contribute to remyelination, either by oligodendrogenesis or 258 
through differentiation into remyelinating Schwann cells73-75, and also hypertrophy and 259 
increase expression of NG2, a proteoglycan thought to mediate entrapment of neurons76. 260 
However, the roles of OPCs in the spinal injury scar have been obscured experimentally by 261 
overlap of markers with other cells. Alongside NG2, PDGFR, two ganglioside antigens, and 262 
a cyclic nucleotide phosphodiesterase (also thought to be expressed in microglia), OPCs also 263 
express the traditional astrocyte marker GFAP, and may differentiate into a de novo population 264 
of astrocytes in the scar72,77. Additionally, both PDGFR and NG2 are also thought to be 265 
expressed by at least one type of perivascular/pericyte-type cell71. The use of fate mapping 266 
transgenic mouse lines, such as those expressing Cre recombinase under control of the 267 
PDGFR promoter/enhancers75,73,74,78, alongside inclusion/exclusion of specific markers, will 268 
further define their contribution to remyelination after spinal cord injury.   269 
 270 
Resident microglia and innate and adaptive immune cells 271 
By 24 hours after spinal cord injury, blood-derived monocytes are recruited into the lesion. 272 
Upon extravasation, DAMPs and the associated reactive and inflammatory environment, 273 
shape their differentiation phenotype. Meanwhile, resident microglia retract cellular processes 274 
and become morphologically indistinguishable from infiltrated monocyte-derived 275 
macrophages. Until recently, microglia and macrophages were only distinguishable using 276 
relative gene expression of CD45 (macrophages being defined as CD11b+, CD45high and 277 
microglia CD11b+, CD45low) or chimeric models. Specific, or enriched, markers for microglia 278 
have now been discovered, including transmembrane protein 119 (Tmem119)79, P2ry12 and 279 
Fc receptor-like S (FCRLS)80. Tracking resident microglia via a genetic strategy has shown 280 
that spared microglia proliferate and repopulate the lesion core alongside monocyte-derived 281 
9 
 
macrophages38 and recent availability of Tmem119 reporter mice81,82will further elucidate the 282 
role of microglia in spinal injury scarring.  283 
 284 
A monocyte-derived or microglia-derived macrophage phenotypic spectrum exists, from pro-285 
inflammatory (M1, secreting TNF, IL-1β, IL-6, IL-12) to pro-repair (M2, secreting IL-10, IL13). 286 
Following spinal cord injury, there is initially a mixed M1/M2 response83 .The release of pro-287 
inflammatory cytokines at the injury site further mobilizes resident and blood-derived cells to 288 
phagocytose debris84,85 and affects the phenotype of other nearby resident cells..  289 
 290 
The adaptive immune system also plays a role. After spinal cord injury, the recruitment of T 291 
cells, and production of proinflammatory IFN occurs within 24hours following injury86. Other 292 
adaptive immune system components are recruited by 7 days, and contribute to non-resolving 293 
trauma-induced autoimmunity87. Leukocytes present DAMP-derived antigens (such as MBP) 294 
to T and B-cells. B cells, in turn, may present antigens to T-cells, triggering their expansion. 295 
Furthermore, B-cells differentiate into plasma cells synthesizing auto-antibodies, further 296 
fuelling a feed-forward immune response88.  297 
 298 
Unlike conditions in which successful wound healing occurs, there is no effective resolution to 299 
cellular recruitment and inflammation after spinal cord injury. Monocyte or microglia-derived 300 
macrophages remain in the injured spinal cord indefinitely89. Macrophages  maintain 45% of 301 
peak activation months after injury90 and their phenotype does not undergo the switch from 302 
pro-inflammatory to pro-repair associated with the next phases of wound-healing in other 303 
organ tissues91. The early arginase1+ (M2-like) differentiating infiltrating population is not 304 
maintained83 and the spectrum of innate immune cell activation phenotype is predominately 305 
M1 polarized. Adaptive immunity is non-resolving, whereby lymphocytes remain indefinitely in 306 
the spinal injury scar. 307 
 308 
Interaction between cell types 309 
The response of astrocytes, OPCs, microglia and infiltrating innate and adaptive immune cells 310 
is continually influenced by one another and the tissue environment (Figure 2 depicts the time 311 
course of reactive resident and non-resident cell recruitment and activation, and their cross-312 
linked interactions which lead to the chronic spinal injury scar). There are multiple direct and 313 
indirect cellular interactions mediated by cytokines and chemokines which underlie this 314 
(alongside interactions which occur via ECM components, discussed below). Perivascular 315 
astrocyte endfeet are an integral part of the endothelial blood spinal cord barrier, and thus 316 
astrocytes are in a position to regulate the magnitude of leukocyte recruitment. Astrocyte 317 
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expression of Socs392 or  NFKB93 increases monocyte infiltration to the lesion epicentre. In 318 
addition, resident and infiltrated microglia/macrophages express a number of receptors for 319 
proinflammatory chemokines and cytokines released by reactive astrocytes (such as IL-6, 320 
IL1β, CCL2), contributing to a cell signalling environment which potentiates M1 polarization. 321 
In turn, astrocytes express receptors for a number of inflammatory mediators released by 322 
immune cells (including IFN, IL6, IL1β, TNF), inducing extensive astrocyte reactivity and 323 
astrogliosis53,94. Thus, there is an intimate link between astrocytes and resident and infiltrating 324 
immune cells during formation of the spinal injury scar. Astrocyte-fibroblast interactions have 325 
been shown to spatially compartmentalise the fibrotic core62 and recent evidence suggests 326 
that microglia may provide an additional interface between these cells, which the authors term 327 
the microglial scar38.  328 
 329 
In addition to direct cellular cross-talk, almost all parenchymal cells express receptors for a 330 
multitude of signalling molecules present in the external injury microenvironment and indirectly 331 
affect cell activation and phenotype of surrounding cells. Within this, there are canonical 332 
regulators. For example, abolishing Wnt signalling in OPCs has been shown to reduce 333 
monocyte accumulation and astrocyte hypertrophy95. Furthermore, neurons themselves are 334 
directly contacted by cells in a manner which inhibits reestablishment of neuronal connectivity. 335 
Proinflammatory ED1/CD68+ macrophages induce axonal dieback upon contact96,97, NG2+ 336 
OPCs mediate neuronal entrapment76, and perivascular Glast 1+ cells are also directly 337 
contacted by stalled axons67. 338 
 339 
Importantly, the reactive cellular responses after spinal cord injury are not effectively resolved 340 
and many aspects are maintained chronically. Macrophages retain activity long-term with 341 
maintained M1 like characteristics. Glia continue to be reactive in regions of tissue spared by 342 
injury and in areas remote from the site of trauma98, partly in response to Wallerian 343 
Degeneration99,100. Proximal to the lesion, glia remain hypertrophic, forming a compacted 344 
astroglial scar border in which spared tissue is permanently isolated from a zone of unresolved 345 
pathology, fibrosis and tissue loss. This zone is not effectively repopulated by neurons or glia 346 
and, in most mammalian species, develops into a chronic cystic cavity (Figure 1). 347 
 348 
Extracellular components of the scar 349 
The CNS ECM is rich in glycoproteins and proteoglycans. Hyaluronan forms a backbone for 350 
the attachment of tenascins and sulphated proteoglycans, stabilised by link proteins. This is 351 
arranged either diffusely in the interstitial space or more densely assembled around the cell 352 
soma of particular neuronal subtypes (as perineuronal nets), or around axonal nodes of 353 
ranvier or synaptic boutons. These structures confer neural stability, localizing molecules such 354 
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as CSPGs, which effectively restrict large-scale plasticity following a critical period in 355 
development101. Following injury, resident glia and also stromal cells, which do not normally 356 
contribute parenchymal matrix, begin to contribute matrix components, and extracellular 357 
DAMPs are present in both sub-acute and chronic phases. 358 
 359 
A  vast number of ECM molecules undergo differential regulation following spinal  cord injury 360 
(for a large scale validation see50) and many of these play a role in neuroprotection or 361 
spontaneous repair and are not refractory to recovery. Fibrous matrix forms a seal or tissue 362 
bridge between retracting lesioned parenchyma. This is particularly apparent in injuries where 363 
spinal tissue is rendered non-continuous, such is the case following hemisection or 364 
transection. Fibroblast-derived collagenous matrix is a major component33 (and in vivo 365 
ablation of fibroblasts compromises tissue integrity following injury)66. Basal laminae is 366 
restored via matrix deposition of collagen VI, nidogen, fibronectin and laminin, which are 367 
traditionally neuronal-growth permissive molecules. However, in the context of spinal cord 368 
injury, such ECM molecules are also implicated in pathological tissue remodelling or 369 
inflammation. For example, fibronectin, matrix glycoprotein tenascin C and hyaluronan 370 
fragments are also endogenous TLR ligands and represent DAMPs48. 371 
 372 
Extracellular components fuel fibrosis and scarring 373 
Initial and expanding secondary pathology generates a large amount of cellular debris, 374 
sustained by longer-term Wallerian degeneration, oligodendrocyte apoptosis and 375 
demyelination. The presence of debris, and its breakdown products, supports an ongoing 376 
foam-cell-like macrophage phenotype102 where ineffective phagocytosis and lipid processing 377 
means extracellular stimuli are maintained85 and are presented to adaptive immune cells, 378 
which contributes to a non-resolving auto-immune response to injury87. Thus, the extracellular 379 
environment is undergoing both chronic inflammation and glial reactivity, associated with 380 
aberrant tissue remodelling and matrix deposition. There is increasing understanding as to 381 
how these processes are intertwined.  382 
 383 
A recent study finds that perivascular PDGFR+ cells (which the authors of the study term 384 
pericytes) upregulate expression of the ECM molecule periostin, which in turn upregulates 385 
TNF expression from infiltrating monocyte-macrophages and leads to proliferation of 386 
PDGFR+ cells, type-I collagen deposition and fibrosis70. Perivascular-derived type-1 387 
collagen has also recently been implicated in linking fibrosis and astrogliosis, where an N-388 
cadherin dependent interaction between extracellular type-1 collagen and astrocytes was 389 
found to induce scar-forming astrogliosis in mice54. Thus, there is an expanding role for 390 
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perivascular Col1α1-cell derived fibrotic matrix described following contusion injury in mice63. 391 
PDGFR+, fibronectin-rich fibrotic matrix deposition is also observed in rats in the peripheral 392 
rim of the cavity and outlining blood vessels103, suggesting a somewhat conserved contribution 393 
despite differences in cavity formation between mice and rats. Matrix deposition of type-1 394 
collagen has also been described as a perivascular-fibroblast-derived scaffold for 395 
neoangiogenesis65. Therefore the role of collagen in fibrosis and angiogenesis in spinal cord 396 
injury requires further study.  397 
 398 
Extracellular components are inhibitory to neural regeneration and plasticity 399 
In addition to an ongoing DAMP role for myelin debris, myelin-associated molecules confer 400 
extrinsic inhibition to neurons. These include Nogo A, myelin-associated glycoprotein (MAG) 401 
and oligodendrocyte myelin glycoprotein (OMgp). Nogo-A is a potent inhibitor to neural 402 
plasticity and regeneration following spinal cord injury104, preventing axons from overcoming 403 
the spinal injury scar environment. Transmembrane receptor complexes are identified, 404 
converging on the canonical RhoA/ROCK signalling pathway, resulting in destabilization of 405 
the actin cytoskeleton and local arrest and collapse of growth cones105. Furthermore, CSPGs 406 
(Box 2) are upregulated by reactive glia following spinal cord injury both perilesionally and at 407 
distal spinal segments98,106  and are associated with decreased plasticity and abortive 408 
regeneration107 . Recent evidence suggests that scar-forming astrocytes express brevican, 409 
and NG2, though not aggrecan108. There is some evidence that core CSPG proteins are 410 
inhibitory to neuronal growth109 but CS-GAG chains are known to confer significant inhibition 411 
following injury as their removal promotes anatomical and functional recovery following spinal 412 
cord injury110. Membrane-bound receptors to CS-GAGs, reported to mediate inhibition, include 413 
RPTPσ111,112, leukocyte common antigen-related phosphatase (LAR)113, NgR1 and NgR3114. 414 
Signalling pathways implicated have convergence with those of Nogo and other myelin 415 
inhibitors and include the Rho/ROCK pathway, activation of which is partly via PKC115 and 416 
EGFR116 and coupled to Akt/GSK-3 activation117. CSPGs are also thought to inactivate neural 417 
intergrins118 and localise upregulated inhibitory guidance molecules such as semaphorin 418 
3A119. Thus, the injured spinal cord contains molecules which restrict neurite outgrowth and 419 
plasticity, and these are further upregulated and concentrated in the spinal injury scar and 420 
represent therapeutic targets120 (discussed below). 421 
 422 
Biomechanical properties of the scar 423 
Relatively little attention has been given to how the biomechanical environment of the injured 424 
spinal cord affects repair121. Cells are highly mechanosensitive and changes in the elastic 425 
properties of the environment alone can induce differentiation and migration122, and during 426 
development mechanical gradients guide axon pathfinding123. Astrocytes that are cultured on 427 
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less compliant, stiff substrates anatomically resemble reactive astrocytes, displaying 428 
hypertrophy and elongation, with stiffness of CNS implants correlating with induction of 429 
reactive astrocytosis124. Integrin-mediated links between fibrillar type 1 collagen (known to be 430 
stiffer in other tissues) and astrocyte reactivity are emerging54, which may be influenced by 431 
mechanotransduction. Atomic force microscopy has been used to characterize the 432 
spatiotemporal elastic stiffness properties of spinal cord tissue over 1 to 3 weeks following  433 
dorsal column crush lesion125. At these early post-injury time points, tissue softened in areas 434 
corresponding to scarring and ECM deposition. This was somewhat surprising because scar 435 
tissue outside the CNS is typically stiffer than surrounding healthy tissue126, and was attributed 436 
to a lack of collagen-1 and loss of CNS myelin in these types of injuries (both of which scale 437 
with tissue stiffness)127,128, as well as the cellular composition of the scar (glial cells are softer 438 
than  peripheral scar myofibroblasts). It will be important to further characterize these 439 
properties in more clinically relevant contusion-type injuries and in chronic injuries with 440 
established scar tissue, particularly given the increasing evidence of a role for collagen-1 in 441 
chronic contusive injuries54,63,129.  442 
 443 
The spinal injury scar: the good, the bad, and the false-dichotomy 444 
There has been some recent debate in the field on whether the scar is good or bad in terms 445 
of recovery from injury108,130-132. We propose that these two different viewpoints reflect different 446 
interpretations of data which is, in fact, largely in agreement. Both historical and newer findings 447 
support a long-established principle, that the spinal injury scar performs dual, and seemingly 448 
opposing, roles; to protect tissue, and to inhibit repair.  449 
 450 
As previously introduced, the classical description of the spinal injury scar is one which 451 
considered the astrocyte-rich injury border alone, termed the glial scar. Early observations of 452 
dense glial reactivity at the site of CNS lesions led to the hypothesis that the astrocytic scar 453 
inhibits axon regeneration, perhaps by forming an impenetrable barrier to axonal extension133. 454 
An inhibitory role for the scar and scar-associated molecules has been well documented ever 455 
since (as discussed above and26,106,107,134,135). However, it has also long been acknowledged 456 
that the astrocytic scar has an important protective role in enabling the separation of healthy 457 
tissue from pathology following injury136-138. Thus, for decades the dual notions that the scar 458 
is associated with failed axonal re-connectivity (inhibitory) and also involved in a wound-459 
healing response (protective), have existed.  460 
 461 
In addition, as discussed above, there is now increased appreciation of the multiple cell types, 462 
beyond astrocytes, which contribute to spinal injury scarring, together with extracellular and 463 
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non-neural components. This renders the term glial scar an insufficient descriptor. The 464 
multifaceted nature of the scar should be considered when interpreting experimental 465 
approaches which prevent scar formation. For example, a number of transgenic loss of 466 
function experiments have been performed to specifically investigate the role of astrocytes 467 
following spinal cord injury, including formation of the glia limitans and continued presence in 468 
the chronic scar. Early evidence suggested that double knockout mice for the intermediate 469 
filament proteins GFAP and vimentin (but not either protein alone) develop a less dense glial 470 
scar, with greater haemorrhaging, fibrosis and presence of debris following lesion to the dorsal 471 
funiculus139. Similarly, conditional ablation of proliferating (scar-forming) reactive astrocytes 472 
following injury increases edema, inflammation, oligodendrocyte death, tissue loss, 473 
demyelination and functional deficits140,141. Furthermore, deletion of SOCS3 or STAT3 in 474 
astrocytes results in lesion expansion, cell death and exacerbated functional outcome58,92. 475 
Thus, a number of studies have provided evidence for the importance of reactive astrocytes 476 
in preventing expansion of pathology into spared peri-lesional regions of the spinal cord. A 477 
recent extension of these studies utilized these deletion strategies to specifically assess the 478 
effects of reactive astrocytes on axonal regeneration108. The study revealed that spontaneous 479 
regrowth of damaged axons does not occur across a spinal crush injury following attenuation 480 
or ablation of scar forming astrocytes, despite boosting the regenerative state of these axons 481 
with a conditioning lesion and neurotrophin delivery108. This study claimed to reveal a new 482 
(and controversial) role of the astrocytic scar as being pro-regenerative. Our interpretation of 483 
these findings, however, is that they are largely consistent with previous studies58,92,141. A lack 484 
of axon regeneration after ablating reactive scar astrocytes does not necessarily mean that 485 
the glial scar aids axon regeneration. An alternative interpretation is that the regenerative 486 
boost afforded by conditioning lesions and neurotrophin delivery is not sufficient to overcome 487 
the prior-established lesion-exacerbating effects of preventing astrocytic scar formation. 488 
Instead, injured axons are presented with neural and non-neural components of the spinal 489 
injury scar, including NG2+ OPCs, inflammatory cells and CSPGs, all of which are known 490 
blockers of regeneration142. Indeed, greater dieback of axons from the injury site was observed 491 
in this study108, in line with an advancing wall of inhibitory factors no longer contained in the 492 
fibrotic lesion core. Thus, rather than overturning an old dogma, this study used elegant 493 
genetic tools to demonstrate an important role for scar-forming astrocytes in tissue protection 494 
following traumatic spinal cord injury, supporting previous observations58,92,141 and confirming 495 
the early hypothesis postulated by Gopal D. Das: “If, by some means, glial scar formation 496 
could be completely eliminated, most of the atrophying axons still might not show 497 
regeneration, and the spinal cord would be continuously invaded by loose connective tissue 498 
and other foreign materials and organisms while undergoing a protracted degeneration”136.   499 
 500 
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Although astrocyte components of the spinal injury scar are well evidenced to be beneficial 501 
initially, they have been suggested to be detrimental at a chronic stage32,143,144. Worsened 502 
functional outcome at 10 weeks post injury following diphtheria toxin-mediated ablation of 503 
astrocytes at 5 weeks has been suggested to support a beneficial role of chronic scarring 108. 504 
However, axon regeneration in this study may have occurred early, prior to scar maturation, 505 
since axons were in a growth-stimulated state131. It is possible that astrocyte ablation at both 506 
early and chronic stages is detrimental, however further studies will be needed to establish 507 
this. A recent proteomic analyses of subacute (2 week) and chronic (8 week) spinal injury scar 508 
tissue revealed differential features in the different post-injury phases, with abundant 509 
expression of growth factors observed subacutely but not chronically, where the signature 510 
instead showed high expression of growth inhibitory ECM molecules including collagens and 511 
CSPGs145. This study also demonstrated increased axonal regeneration across a complete 512 
spinal transection injury after surgical removal of chronic scar tissue. Taken together, this data 513 
supports a beneficial role for early scarring and an inhibitory role for chronic scarring. It will be 514 
important to further characterise the molecular profile of the spinal injury scar at precise time 515 
points after injury, both for the cell types involved in scarring (e.g. Box 1) as well as features 516 
of the environment. 517 
 518 
Thus, the dual nature of the spinal injury scar has long been known, yet continues to be 519 
reviewed, revisited and reinterpreted19,64,92,108,132,143,144,146. Rather than focus on good versus 520 
bad, perhaps efforts would be best directed at understanding and targeting specific aspects 521 
of the scar to aid recovery. For example, it may be beneficial to target components of the scar 522 
which are non-permissive to regeneration or plasticity rather than removal of the astrocytes 523 
themselves, even at chronic time-points. Targeting diverse cell types and phenotypes, as well 524 
as extracellular and non-neural components should also be considered, as well as the timings 525 
of such interventions. These approaches will be discussed in the following section. 526 
 527 
 528 
Therapeutic strategies 529 
Current experimental approaches for targeting the spinal injury scar attempt to either reduce 530 
scar formation, or to block inhibitory molecules associated with the scar, using a variety of 531 
surgical, pharmacological and genetic approaches. Some of these show promise for 532 
application in the clinic. 533 
 534 
Attenuating scar formation 535 
Although preventing formation of the astrocytic component of the spinal injury scar  impacts 536 
negatively on wound-healing (discussed above), as the mechanistic understanding of spinal 537 
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injury scar pathology increases, a number of studies in preclinical rodent models have targeted 538 
mesenchymal or fibrotic-derived components in a bid to limit amplification of tissue damage. 539 
On a gross tissue scale, if the dura is breached, dural apposition and/or patching with another 540 
soft tissue material (duraplasty) is suggested to limit fibrotic and connective tissue deposition 541 
from meningeal-derived fibroblasts147. Decompressive durotomy followed by dural allograft 542 
has been shown to reduce scar formation and lesion volume, but if the dura is not replaced, 543 
lesion volume increases dramatically147 and indeed expansion duroplasty is performed 544 
alongside decompressive durototomy in clinical evaulations148. 545 
 546 
The fibrotic components of the scar can also be targeted pharmacologically. Systemic 547 
administration of the microtubule stabilizing antimitotic agents taxol or Epothilone B leads to 548 
reduced migration of scar-forming fibroblasts and suppression of extensive scar formation, 549 
enabling axon regeneration and functional recovery149 11. This highlights the potential for 550 
repurposing of epothilones and taxanes that are already used in cancer treatment150. Inhibiting 551 
collagen synthesis using the iron chelators BPY-DCA (which inhibits prolyl 4-hydroxylase, a 552 
key enzyme of collagen IV synthesis) and cyclic adenosine monophosphate (cAMP, which 553 
inhibits meningeal fibroblast proliferation)151,152 reduces fibrotic scarring and promotes 554 
neuroprotection and long-distance axon regeneration151. Treatment with clinically approved 555 
ion chelator deferoxamine and inhibition of lysl oxidase, another key collagen biosynthetic 556 
enzyme, also improves outcome after partial spinal transection injuries in rodents153,154.   557 
 558 
The gene expression profile or phenotype of astrocytes may also represent potential 559 
therapeutic targets with modulating effects on scar formation. For example, selective inhibition 560 
of NFB signalling in astrocytes reduces inflammation and is pro-reparatory in mice 561 
expressing a dominant negative B under the GFAP promoter93. However, this is difficult to 562 
target therapeutically. If current studies of astrocyte phenotype in the mouse brain (Box 1) 563 
translate experimentally to the injured spinal cord, newly identified gene/signalling targets and 564 
matrix targets (below) could be manipulated to depress propagating scar pathology. In vitro, 565 
application of human recombinant TGFβ3 (but not the removal of mediators IL1, TNF and 566 
C1q) was able to rapidly reverse transformation from an A1 phenotype to an unreactive 567 
status94. Following optic nerve crush, this phenotypic conversion was demonstrated in vivo by 568 
delivery of antibodies to IL1, TNF and C1q94. Manipulation of TGFβ3 was not reported in 569 
vivo, however multiple studies have targeted TGFβ1&2 following spinal cord injury155 to reduce 570 
spinal injury scar formation, so it would be interesting to know whether this is a TGFβ3-specific 571 
effect. Indeed TGFβ 1 and 2 are known to exert opposing effects to TGFβ3 on wound healing 572 
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outside of the CNS, and human recombinant TGFβ3 has been utilized in clinical trials to 573 
promote dermal wound healing and scar reduction156. 574 
 575 
 576 
Targeting the extracellular matrix  577 
Following spinal cord injury, the extracellular environment contains molecules which interact 578 
directly with neurons and other cell types (discussed above). Some of these are thought to 579 
augment pathology and degree of spinal injury scarring, while some directly inhibit the ability 580 
of neurons to overcome a scar environment and generate novel connectivity. Both are 581 
potential therapeutic targets. 582 
 583 
Periostin is a secreted ECM protein which has recently been implicated in contributing to scar 584 
formation, via propagating fibrosis and inflammatory signalling50,70. Daily intraperitoneal 585 
injections with a mouse monoclonal antibody against periostin from 4 days to 2 weeks after 586 
injury was shown to reduce the extent of tissue pathology and scarring, which led to functional 587 
improvements in sensorimotor tasks following contusion injury in mice70. Generation of 588 
recombinant anti-periostin will allow this promising strategy to be further tested. Similarly, a 589 
recent study found that pathology could be attenuated within the first 2 weeks following spinal 590 
cord injury in mice treated with an N-cadherin neutralizing antibody, which blocked an integrin 591 
and N-cadherin dependent interaction between extracellular type-1 collagen and astrocytes 592 
and significantly attenuated astrocytic scar formation54. In this study the rapid behavioural 593 
recovery observed supports a neuroprotective role for neutralising n-cadherin, though this was 594 
not assessed directly. As above, these studies suggest that early fibrosis is an important 595 
therapeutic target for improving outcome after spinal cord injury. Furthermore, if A1/A2 596 
polarisation factors94 are conserved following spinal cord injury, a known inhibitor of C1q is  597 
chondroitin sulfate A157, the mono CS-4 sulfated GAG, which raises interesting questions 598 
regarding additional roles of ECM proteoglycans and their sulfation epitopes following injury. 599 
Thus, matrix properties are a valuable means to tap into the plasticity of cell responses. 600 
 601 
CSPGs (see Box 2) are known inhibitors of neuronal plasticity, present throughout the CNS 602 
ECM and highly concentrated in the spinal injury scar (discussed above). A number of 603 
experimental studies have reported functional improvement following spinal cord injury by 604 
genetic removal of enzymes critical for CS-GAG biosynthesis. This includes deoxyribozyme-605 
mediated knockdown of xylosyltransferase-1 mRNA, the enzyme which catalyses GAG 606 
addition to the CSPG core protein158, conditional sox9 ablation159 and knockout of N-607 
acetylegalactosaminyltransferase-1, the enzyme which catalyses the addition of the first 608 
GalNAc residue onto the tetrasaccharide link between the core PG and GAG160. Reports of 609 
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therapeutically-applicable pharmacological approaches which recapitulate these effects are 610 
currently lacking. 611 
 612 
Enzymatic strategies targeting CSPGs are a promising approach for spinal cord repair, due to 613 
their ability to render the ECM more permissive to neuronal plasticity and connectivity. 614 
Removal of CS-GAGs by the chondroitinase ABC (ChABC) enzyme has been widely 615 
demonstrated to have beneficial effects in enhancing axonal regeneration and neuroplasticity 616 
and promoting functional recovery following experimental spinal cord injury110,161.162-164. This 617 
effect has been replicated across multiple laboratories and in different species165, including 618 
mouse, rat, cat, and recently in primates166 and in a canine clinical model167. Furthermore, its 619 
use as an adjunct therapy can augment the benefits of other experimental therapeutics168-170. 620 
A gene therapy method of enzyme delivery, where host cells are themselves transduced to 621 
express the ChABC gene leads to extensive CS-GAG digestion, which results in reduced 622 
pathology and improved functional recovery following contusion injury to the thoracic171 and 623 
cervical172,173 spinal cord. Furthermore, widespread CSPG modulation achieved by viral 624 
delivery of ChABC promotes conversion of macrophages towards a pro-resolving M2 625 
polarization state171 and drives an anti-inflammatory IL-10-mediated response174, which is 626 
likely to underlie reduced pathology. Thus, ChABC is a promising means to promote resolution 627 
of pathology as well as overcoming the inhibitory environment of the spinal injury scar. A 628 
recent study utilised a novel gene switch to enable controlled delivery of the ChABC gene and 629 
revealed that long term ChABC gene expression was required to elicit recovery of skilled reach 630 
and grasp functions, with recovery attributed to plasticity of descending systems173. Whether 631 
this viral ChABC approach will also have benefit when applied chronically is not yet 632 
established. However, recent work has demonstrated that a single injection of ChABC enzyme 633 
in the phrenic motor pool 1.5 years after unilateral cervical spinal cord injury was able to elicit 634 
rapid and robust recovery of respiratory function, restoring the ventilatory response to the 635 
paralysed hemidiaphragm175. Furthermore, chronic application of ChABC prior to 636 
transplantation of induced pluripotent stem cell-derived neural stem cells 7 weeks after a 637 
spinal compression injury led to reduced chronic-injury scarring, increased graft survival and 638 
improved limb function176. These studies highlight the potential for ChABC to unmask latent 639 
neuroplasticity and produce a microenvironment conducive to repair even within the chronic 640 
spinal injury scar. 641 
 642 
Another enzymatic strategy that has recently been exploited for reducing CSPG inhibition is 643 
the mammalian enzyme Arylsulfatase B (ARSB, N-acetylgalatosamine-4-sulfatase), which 644 
removes C4S moieties specifically from CS-GAGs. In addition to being utilized in enzyme-645 
replacement therapy for human mucopolysaccharidosis VI, ARSB administration has now 646 
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been shown in one study to promote increased axonal sprouting and functional locomotor 647 
recovery following compression spinal cord injury in the mouse177. ARSB perhaps represents 648 
a more attractive, and more readily translatable, therapeutic prospect than a bacterial enzyme 649 
such as ChABC and certainly warrants further investigation, particularly given recent findings 650 
of eliciting enhanced axon growth in the injured optic nerve178. However, whether ARSB could 651 
elicit robust modulatory effects within the spinal injury scar microenvironment, comparable to 652 
ChABC, remains to be determined. Given the specificity of ARSB for 4S motifs, it may not be 653 
capable of the multi-modulatory effects that have been demonstrated for ChABC which include 654 
immune modulation, neuroprotection and neuroplasticity165,179,180. 655 
  656 
Targeted modulation of CSPG receptor signalling via manipulation of the receptor PTPσ, has 657 
also proved to be a promising therapeutic prospect. The activity of the intracellular 658 
phosphatase domains of PTPσ are regulated via a conserved “wedge” structure which can 659 
occlude the catalytic domain, thus reducing phosphorylation activity and ability to signal 660 
downstream. Use of a membrane-permeable peptide mimetic of this wedge reduces PTPσ 661 
signalling following activation by ligands such as CSPGs. Systemic delivery of this peptide 662 
has been shown to enable recovery of locomotor and bladder function in rats following spinal 663 
contusion injury181 and the non-invasive nature of this approach means it is a realistic 664 
candidate for rapid translation. Thus, approaches to overcome the inhibitory actions of CSPGs 665 
show collective promise in enabling beneficial alterations to the ECM associated with the 666 
spinal injury scar with positive effects in eliciting some functional repair. 667 
 668 
Future directions for therapy 669 
The majority of approaches aimed at manipulating the spinal injury scar for therapeutic benefit 670 
have focused on modifying scar-associated ECM and targeting the synthesis, production and 671 
signalling of CSPGs. With the identification of cell subtypes that have opposing actions on 672 
tissue pathology, such as A1 neurotoxic vs A2 reparatory astrocytes94, there may be further 673 
opportunity to modulate astrocyte function or phenotype following spinal cord injury. These 674 
approaches will likely evolve as new markers are identified for delineating reactive astrocytes 675 
and microglia in different phenotypic states182, with increasing availability of astrocyte and 676 
microglia cell-specific sequencing data54,79,108 and with powerful emerging tissue sequencing 677 
technology183. Alternative approaches which may indirectly modulate astrocyte phenotype are 678 
also emerging, such as grafting specific stem cell populations which can influence host tissue 679 
cellular responses and drive astrocyte transformation to a permissive phenotype132. 680 
Additionally, with increased appreciation for the role of  ECM molecules in affecting pathology 681 
and plasticity of cellular responses, novel targets may be identified with new matrix biology 682 
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technology184. Conversely, the study of scarring mechanisms and ECM components in 683 
organisms that are capable of CNS regeneration may lead to the identification of pro-repair 684 
targets. For example, differential regulation of collagen XII within the scar matrix is one factor 685 
contributing to the pro-regenerative phenotype in zebrafish, controlled by Wnt/B catenin 686 
signalling185.  Whether Wnt/B-catenin-mediated collagen XII production can be harnessed to 687 
render the mammalian spinal injury scar more permissive is not yet known. Finally, 688 
consideration should be given to scar biomechanics121,125 when designing therapies. It may be 689 
important to understand how pharmacological manipulations affect mechanobiology and 690 
further provide appropriate mechanical signals to optimize repair.  691 
 692 
Conclusion 693 
The spinal injury scar is multifaceted. It contains more than just a reactive glial component 694 
and should be considered as a whole, since there is a complex interplay between multiple 695 
different cell types (glial cells, mesenchymal-derived cells, immune cells), their intracellular 696 
and signalling changes, and the extracellular environment. These processes modulate and 697 
feedback on each other. Altering the environment, for example using CSPG modulation with 698 
chondroitinase, can increase neuronal regeneration-associated gene expression and 699 
transcriptional changes110,174. Conversely, altering intracellular mechanisms can alter the 700 
inhibitory environment (for example microtubule stabilization with taxol or epothilone B leads 701 
to reduced fibrotic scarring149). Similarly, astrocyte-immune cell interactions are bidirectional, 702 
where an increasingly proinflammatory environment induces extensive astrogliosis53 and in 703 
turn, activated astrocytes release pro-inflammatory cytokines, chemokines and CSPGs, which 704 
can influence the magnitude of the inflammatory response22. The spinal injury scar has both 705 
beneficial properties (being essential for preventing spread of cellular damage) and 706 
detrimental properties (limiting new growth and tissue repair). This may be attributable to 707 
opposing phenotypes of reactive glial cells that form the scar border, given recent evidence in 708 
other CNS pathologies94. However, also important to note are the opposing roles of the scar 709 
matrix which contains beneficial molecules, required for formation of the glia limitans (which if 710 
not formed properly, can increase damage and worsen outcome) as well as molecules that 711 
are potent inhibitors of growth and neuroplasticity, such as CSPGs. Therapeutic strategies 712 
need to target detrimental aspects while preserving the beneficial properties of the spinal injury 713 
scar. Increased mechanistic understanding of the biological processes that propagate the non-714 
resolving scar pathology is providing new therapeutic targets which may bring us closer to 715 
improving functional outcome following traumatic spinal cord injury. 716 
 717 
 718 
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Box 1: Phenotypic diversity and plasticity of astrocytes: emerging evidence from 719 
brain and spinal cord injury 720 
There is increasing data available on the cellular profile and phenotypic diversity of astrocytes 721 
after injury. Phenotypic nomenclature comparable to that adopted in characterization of 722 
macrophages/microglia has been used for the transcriptional profiling of cultured astrocytes 723 
isolated from the CNS under different injury conditions. Ischemic injury in the brain (modelling 724 
stroke) leads to a trophic A2 polarization state. By contrast,  activated microglia from models 725 
of neurodegenerative and neuroinflammatory diseases and traumatic optic nerve crush injury 726 
release factors such as IL1, TNF and complement component subunit 1q (C1q) which induce 727 
a neurotoxic state in A1 astrocytes55,94. In the optic nerve, there is evidence that axotomy-728 
induced A1 astrocytes, in turn, kill axotomized neurons. In these studies, microglial-derived 729 
mediators were necessary and sufficient to induce an A1 phenotype. Whether this occurs 730 
following spinal cord injury is, as yet, unreported.  731 
 732 
Genetic profiling of reactive astrocytes and scar-forming astrocytes following spinal cord injury 733 
(isolated by laser-capture microdissection at 7 and 14 days post injury, respectively) has 734 
recently been reported. Reactive astrocytes were associated with selective upregulation of 735 
Nes, Ctnnb1, Axin2, Plaur, Mmp2, and Mmp13 whereas scar-forming astrocytes selectively 736 
upregulated Cdh2, Sox9, Xylt1, Chst11, Csgalnact1, Acan, Pcan and Slit254. Furthermore, 737 
using these genes as population markers, FACs isolated nestin-GFP+ reactive astrocytes 738 
were found to convert to a naïve phenotype following transplantation into uninjured tissue but 739 
become scar-forming when transplanted into injured tissue, an effect thought to be mediated 740 
by a N-cadherin-dependent interaction with type 1 collagen54. Thus, astrocytes are able to 741 
display phenotypic plasticity, and tissue environment is a crucial influence over cellular 742 
behaviour. 743 
 744 
The GFAP-RiboTag mouse can be used to perform high-throughput RNA sequencing on 745 
astrocytes following injury and probe the effect of particular genes in the astrocyte response108. 746 
Two weeks after a spinal crush injury RNA-seq revealed differential expression of over 6000 747 
genes in astrocytes, changes described as congruent with prior transcriptomic analysis 748 
following ischemic stroke lesion55,108. However, whether the astrocytes sampled here 749 
represent A2-like trophic astrocytes has not been ascertained.  750 
 751 
There are some discrepancies between gene expression findings using these different 752 
methodologies. For example, of the 8 genes associated with scar-forming astrocytes isolated 753 
using laser capture microdissection54, the RNA-seq dataset only supports increased 754 
expression in one of these (Xylt1)108, whereas 4 of the 6 genes ascribed to reactive 755 
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astrocytes54, are increased (Nes, Axin2, Plaur, Mmp2)108. Spatial differences in sample 756 
selection may contribute to these disparities. Techniques such as 3D intact-tissue RNA 757 
sequencing183 may overcome this problem in the future. Indeed, further characterization of 758 
spatio-temporal phenotypic diversity and plasticity would aid research into how astrocyte 759 
phenotype and scar progression may be modified by changes to matrix components or 760 
perturbation of the immune response. Such methods, alongside new purification techniques 761 
for in vitro analysis, will likely provide increasingly nuanced understanding of the relationship 762 
between astrocytes, microglia, non-resident immune cells and the tissue environment79,186 . 763 
 764 
 765 
Box 2: Structure of chondroitin sulfate proteoglycans (CSPGs) 766 
CSPGs are proteoglycans (PGs) consisting of a core protein with at least one covalently 767 
attached chondroitin sulfate glycosaminoglycan (CS-GAG) side chain. CSPG subtypes most 768 
commonly studied with respect to the inhibitory CNS environment include lecticans (aggrecan, 769 
versican, neurocan and brevican), the transmembrane protein NG2, phosphacan 770 
(transmembrane or soluble) and the small leucine-rich proteoglycans decorin and biglycan. 771 
There are also multiple less-well studied CSPGs revealed by proteomics analysis of scar 772 
matrix50. Lecticans are the most abundant CSPGs in the spinal injury scar and also feature 773 
globular domains: the G1 N-terminal domain and G3 C-terminal domains are important in their 774 
interaction via link-protein with hyaluronan (the backbone glycoprotein of the CNS matrix) and 775 
also tenascin, thus they are involved in matrix crosslinking. Core PGs undergo post-776 
translational modification in the endoplasmic reticulum and golgi, catalysed by a number of 777 
enzymes. At particular serine residues a tetrasaccharide linking region is formed by sequential 778 
addition of xylose by xylosyl transferase, two galactose molecules by β1,4-779 
Galactosyltransferase-I then β1,3-Galactosyltransferase-II and a one GlcA residue via  β1,3-780 
glucuronyltransferase I to form the linker GlcAβ1–3 Galβ1–3 Galβ1–4 Xylβ1–O-Ser. The 781 
following addition of GalNac by a GalNac transferase I is crucial to initiate synthesis of the 782 
chondroitin sulfate backbone. If, at this point, N-acetylglucosamine (GlcNac) is added rather 783 
than GalNac, synthesis of the heparan sulfate backbone is initiated.187 CS-GAG chain 784 
polymerisation is the process by which alternating residues of GalNac and GlcA are then 785 
added to the proteoglycan linker region by the alternating activity of a GlcA transferase II and 786 
a GalNac transferase II. There are six actual enzymes identified which confer this 787 
glycosyltransferase activity. Alongside CS-GalNac transferase I and II, combinations of 788 
enzyme complexes of chondroitin synthase 1,2 and 3 and chondroitin polymerising factor 789 
(ChPF) mediate GAG polymerization. 790 
 791 
 792 
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Figure Legends 805 
Figure 1. Cellular and extracellular composition of the spinal injury scar.  806 
Traumatic spinal cord injury triggers a complex cascade of events that culminate in the spinal 807 
injury scar which consists of multiple cell types as well as extracellular and non-neural 808 
components. a) in the acute post-injury phase (0-72 hours), cell death and damage lead to 809 
release of a number of cellular and blood-derived DAMPs (damage associated molecular 810 
patterns). These are powerful activating and inflammatory stimuli for stromal cells, astrocytes, 811 
NG2+OPCs and microglia. Fibroblast-like cells proliferate from perivascular origin. Activated 812 
cells increase deposition of extracellular matrix molecules such as chondroitin sulfate 813 
proteoglycans (CSPGs) and stromal-derived matrix. Circulating immune-responders 814 
(neutrophils, monocytes) are recruited, their relative expression of cytokines, chemokines and 815 
matrix metalloproteinases becomes shaped by the early injury environment, and a mixed 816 
immune cell phenotype (M1, pro-inflammatory; M2, pro-resolving) is initially adopted. This 817 
becomes increasingly proinflammatory. b) in the chronic spinal injury scar, monocyte-derived 818 
macrophages/microglia adopt a predominantly M1 phenotype. Rather than entering a phase 819 
of resolution, responding innate immune cells present DAMPs to circulating adaptive immune 820 
cells and pathology spreads. Reactive astrocytes hypertrophy, upregulate expression of 821 
intermediate-filament associated proteins and secrete matrix CSPGs. Fibroblast-like cells 822 
contribute to fibrotic tissue remodelling and deposition of stromal-derived matrix. Innate 823 
immune cells become unable to process cellular and matrix debris effectively and become 824 
synonymous with lipid-rich foam cells. Scar-forming reactive astrocytes organise into a barrier-825 
like structure which separates spared tissue from a central region of inflammation and fibrosis 826 
where wound-healing fails to undergo resolution. In most mammalian species a chronic cystic 827 
cavity develops. Wallerian degeneration of injured axonal projections contributes to continued 828 
extracellular deposition of axonal and myelin debris, which is ineffectively processed by 829 
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immune cells, and along with CSPGs, acts to inhibit neuronal regeneration and neuroplasticity 830 
long-term. 831 
 832 
Figure 2. From injury to scar: time course of progressive scar pathology showing interlinked 833 
relationships between different components of the spinal injury scar.  834 
Following traumatic spinal cord injury, acute cell death and damage triggers release of cell-835 
derived and blood-derived DAMPs, ATP release, dysregulated ionic homeostasis oxidative 836 
stress and excitotoxicity, which represent potent stimuli for triggering glial cell activation, 837 
stromal cell proliferation, deposition of extracellular matrix (ECM), and recruitment of 838 
circulating innate immune cells. Within a few days following injury, monocyte-derived 839 
macrophage/microglia adopt a predominantly “M1” phenotype which do not favour resolution 840 
and tissue remodelling becomes fibrotic. Proinflammatory innate responders also present 841 
DAMP-derived antigens (such as MBP) to T and B-cells. B cells, in turn, may present antigens 842 
to T-cells, triggering their expansion. During this time, reactive astrocytes proliferate, 843 
hypertrophy and overlap in order to isolate this zone of nonresolving pathology from spared 844 
tissue. They also secrete matrix CSPGs, which are known to downregulate neuronal plasticity. 845 
Wallarian degeneration of degenerating axonal tracts contributes to continued deposition of 846 
axonal and myelin debris, which is ineffectively processed by immune cells and leads to the 847 
deposition of myelin-associated molecules (MAG, Nogo, OMgp) which are known inhibitors of 848 
neuronal regrowth. Ongoing Wallerian degeneration at later post-injury stages further triggers 849 
gliosis and neuroinflammation. Dashed grey arrows show cross talk between different 850 
components of the spinal injury scar, which is usually bidirectional. For example, CSPGs 851 
released by reactive astrocytes are thought to activate receptors on macrophages/microglia 852 
to induce a proinflammatory phenotype and in turn increasing inflammation induces further 853 
astrocytic reactivity and CSPG deposition. Fibroblast-like cells also synthesise type 1 854 
collagen, implicated in the induction of astrogliosis and further deposition of matrix molecules. 855 
Cross talk between the innate and adaptive immune response also propagates inflammatory 856 
pathology and further influences glial activation and CSPG production. The dynamic 857 
interactions between inflammation, dramatic tissue and ECM remodelling and reactive cellular 858 
and extracellular changes drive the progressive, propagating pathology that culminates in the 859 
spinal injury scar. 860 
 861 
 862 
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